Trial · NCT06746116
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
NCT06746116, Phase 3, Active not recruiting, AstraZeneca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain. Trials, record NCT06746116. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06746116
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
- NCT number
- NCT06746116
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 45 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Advanced or Recurrent Endometrial Cancer
- Interventions
- Durvalumab + Chemotherapy phase, Durvalumab + Olaparib phase
- First posted
- 2024-12-24
- Last updated
- 2026-07-17
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of patients with Adverse Events | Time from enrollment up to at least 90 days after last dose of study treatment | Safety and tolerability will be evaluated in terms of Adverse Events (AEs), Serious AEs (SAEs), and immune-mediated AEs (imAEs) |
| Secondary | Progression Free Survival (PFS) | From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months) | Defined as the time from the date of first dose of treatment until the date of objective disease progression or death (by any cause in the absence of progression). The measure of interest is the median PFS. |
| Secondary | Objective Response Rate (ORR) | From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months) | Defined as the percentage of patients with a confirmed investigator-assessed response of CR or PR and will be based on a subset of all included patients with measurable disease at baseline per the site investigator. |
| Secondary | Duration of Response (DoR) | From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months) | Defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of disease progression. |
| Secondary | Overall Survival (OS) | From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months) | Defined as the time from the date of first dose of treatment2 until death from any cause. |
| Secondary | Change in EORTC QLQ-C30 score | From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months) | Change from baseline (enrollment) in EORTC QLQ-C30 score every 12 weeks until end of treatment or disease progression. |
| Secondary | Change in EORTC QLQ-EN24 score | From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months) | Change from baseline (enrollment) in EORTC QLQ-EN24 score every 12 weeks until end of treatment or disease progression. |
| Secondary | Clinically meaningful deterioration | From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months) | Percentage of patients having absolute change in EORTC-QLQ-C30 and EORTC-QLQ-EN24 score from baseline of ≥10 at 6, 12, 24 and 36 months after LSI. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06746116
GET https://conductscience.org/api/trials/v1/NCT06746116/registered